Neural stem cell therapy - Stemedica Cell Technologies

Drug Profile

Neural stem cell therapy - Stemedica Cell Technologies

Alternative Names: Ischaemia-tolerant neural stem cells; itNSC; Stemedyne™ NSC

Latest Information Update: 28 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Stemedica Cell Technologies
  • Developer Novastem; S.N. Fyodorov Eye Microsurgery Complex; Stanford University School of Medicine; Stemedica Cell Technologies; Swiss Federal Institute of Technology - Lausanne
  • Class Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Alzheimer's disease; Diabetic retinopathy; Spinal cord injuries; Stroke
  • Discontinued Parkinson's disease

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for clinical-Phase-Unknown development in Stroke in Mexico (Intrathecal)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in Switzerland (Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Spinal-cord-injuries in USA (Intraspinal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top